MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC

Min, Dong-Joon; Ezponda, Teresa; Kim, M. K.; Will, Christine M.; Martínez-García, Eva; Popovic, Relja; Basrur, Venkatesha; Elenitoba-Johnson, Kojo S.J.; Licht, Jonathan D.

doi:10.1038/leu.2012.269

Cited by 76 publications

(72 citation statements)

References 53 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[74][75][76][77] Although MMSET-derived peptides were frequently identified on t(4;14) myeloma samples, we also detected MMSET peptides in the HLA ligandomes of a t(4;14)-negative patient and 1 t(4;14)-negative MCL (U266). Strikingly, functional characterization by ELISPOT revealed memory T-cell responses targeting these MMSET-derived epitopes exclusively in myeloma patients and not in HV.…”

Section: Discussionmentioning

confidence: 90%

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

Walz

Stickel

Kowalewski

et al. 2015

Blood

View full text Add to dashboard Cite

Key Points• Direct analysis of the HLApresented peptidome identifies a distinct antigenic signature in MM.• T-cell responses for these antigens are detectable exclusively in MM patients and can be induced in vitro in response-naive patients.Direct analysis of HLA-presented antigens by mass spectrometry provides a comprehensive view on the antigenic landscape of different tissues/malignancies and enables the identification of novel, pathophysiologically relevant T-cell epitopes. Here, we present a systematic and comparative study of the HLA class I and II presented, nonmutant antigenome of multiple myeloma (MM). Quantification of HLA surface expression revealed elevated HLA molecule counts on malignant plasma cells compared with normal B cells, excluding relevant HLA downregulation in MM. Analyzing the presentation of established myeloma-associated T-cell antigens on the HLA ligandome level, we found a substantial proportion of antigens to be only infrequently presented on primary myelomas or to display suboptimal degrees of myeloma specificity. However, unsupervised analysis of our extensive HLA ligand data set delineated a panel of 58 highly specific myeloma-associated antigens (including multiple myeloma SET domain containing protein) which are characterized by frequent and exclusive presentation on myeloma samples. Functional characterization of these target antigens revealed peptide-specific, preexisting CD8 1 T-cell responses exclusively in myeloma patients, which is indicative of pathophysiological relevance.Furthermore, in vitro priming experiments revealed that peptide-specific T-cell responses can be induced in response-naive myeloma patients. Together, our results serve to guide antigen selection for T-cell-based immunotherapy of MM. (Blood. 2015;126(10):1203-1213

show abstract

Section: Discussionmentioning

confidence: 90%

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

Walz

Stickel

Kowalewski

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…But we have not identified the exact adhesion molecule(s) nor cytokine(s)/chemokines(s) mediating the colonization process (data not shown). It is reported that NSD2 can promote myeloma proliferation by modulating c-MYC through microRNA (50). Whether microRNA network is involved in NSD2-mediated myelomagenesis requires further investigation.…”

Section: Challenges Of Targeting Epigenetic Modulators For Therapymentioning

confidence: 99%

NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

Huang

Chuai

et al. 2013

Cancer Research

View full text Add to dashboard Cite

Histone lysine methyltransferase NSD2 (WHSC1/MMSET) is overexpressed frequently in multiple myeloma due to the t(4;14) translocation associated with 15% to 20% of cases of this disease. NSD2 has been found to be involved in myelomagenesis, suggesting it may offer a novel therapeutic target. Here we show that NSD2 methyltransferase activity is crucial for clonogenicity, adherence, and proliferation of multiple myeloma cells on bone marrow stroma in vitro and that NSD2 is required for tumorigenesis of t(4;14)þ but not t(4;14)À multiple myeloma cells in vivo. The PHD domains in NSD2 were important for its cellular activity and biological function through recruiting NSD2 to its oncogenic target genes and driving their transcriptional activation. By strengthening its disease linkage and deepening insights into its mechanism of action, this study provides a strategy to therapeutically target NSD2 in multiple myeloma patients with a t(4;14) translocation. Cancer Res; 73(20); 6277-88. Ó2013 AACR.

show abstract

“…However, the excess H3K36me2 forces local accumulation of H3K27me3 at a subset of genes, including tumor suppressors. MM cells with t(4;14) translocation are sensitive to EZH2 inhibitors, indicating that the accumulation of EZH2 and H3K27me3 at tumor suppressor loci enhances myeloma cell proliferation [18,65]. Interestingly, in other cancers besides MM, EZH2 and NSD2 are coregulated in an EZH2/NSD2 oncogenic axis [66].…”

mentioning

confidence: 99%

H3K36 Methyltransferases as Cancer Drug Targets: Rationale and Perspectives for Inhibitor Development

2016

View full text Add to dashboard Cite

Methylation at histone 3, lysine 36 (H3K36) is a conserved epigenetic mark regulating gene transcription, alternative splicing and DNA repair. Genes encoding H3K36 methyltransferases (KMTases) are commonly overexpressed, mutated or involved in chromosomal translocations in cancer. Molecular biology studies have demonstrated that H3K36 KMTases regulate oncogenic transcriptional programs. Structural studies of the catalytic SET domain of H3K36 KMTases have revealed intriguing opportunities for design of small molecule inhibitors. Nevertheless, potent inhibitors for most H3K36 KMTases have not yet been developed, underlining the challenges associated with this target class. As we now have strong evidence linking H3K36 KMTases to cancer, drug development efforts are predicted to yield novel compounds in the near future. Cellular development and differentiation are controlled by post-translational modifications on DNA and histone proteins, forming an epigenetic (above the genes) regulatory network. Disruption of epigenetic pathways is a nearly universal feature of cancer, causing aberrations in gene expression and genome integrity (reviewed in [1]). A key group of epigenetic enzymes disrupted in cancer is the lysine methyltransferases (KMTases), which install methyl groups on histone proteins. In cancer cells, methylation performed by KMTases drives proliferation and halts differentiation by modifying gene transcription and other DNA-templated processes [2][3][4]. Over the past decade, KMTases have emerged as important drug targets for both industrial and academic research groups. Some progress has been made, most notably by selective inhibitors for the EZH2 and DOT1L KMTases that have reached clinical trials for the treatment of nonHodgkin lymphoma and acute leukemia, respectively [5,6]. Nevertheless, selective and cell permeable inhibitors for many KMTases remain unavailable.Methylation at H3K36 represents a particularly important chromatin mark implicated in diverse forms of cancer. KMTases with specificity toward H3K36 are overexpressed in cancer cells and have been characterized as regulators of cell growth, differentiation, stemness and DNA repair pathways [7][8][9]. However, very few selective and cell-active small molecule inhibitors of H3K36-specfic KMTases have been reported to date. In this article, we provide an overview of cellular pathways involving H3K36 methylation and discuss the diverse functions carried out by the eight different human H3K36-specific KMTases. Then we analyze structural characteristics of the catalytic SET domain of H3K36 KMTases and evaluate prospects for their inhibition by small molecules. Review Rogawski, Grembecka & Cierpicki We conclude with a discussion of the challenges and o pportunities for targeting these proteins. SPECIAL FOCUS y Epigenetic drug discovery H3K36 methylation regulates diverse processes implicated in cancerH3K36 methylation participates in a wide variety of nuclear pathways. Many of these processes, including transcriptional regulation, alternative spli...

show abstract

MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC

Cited by 76 publications

References 53 publications

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

H3K36 Methyltransferases as Cancer Drug Targets: Rationale and Perspectives for Inhibitor Development

Contact Info

Product

Resources

About